RIBOMIC, Inc. has announced that the first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. Currently approved therapies […]
This is becoming a common question among people who have been treated for years with anti-VEGF drug therapy. These eye injections are the gold standard for treatment of wet age-related macular degeneration (wAMD), having been first used clinically in 2004. The news is good. A recent retrospective review in the U.K. has found that almost […]
Researchers have discovered a protein that might be related to the cause of age-related macular degeneration (AMD) and thus provide insight into early diagnosis and treatment. The study, published in Nature Communications, was a collaboration of Queen Mary University of London, the University of Manchester, Cardiff University, and Radboud University Medical Center, Nijmegen. High levels […]
For over two decades, eye health organizations have worked diligently to increase awareness of the high risks of macular degeneration from tobacco smoking. Now, the recently-released 2020 Surgeon General’s report has revealed that the work of those organizations is paying off. Americans are doing better at making good choices when it comes to smoking. According […]
A presentation to the International Low Vision Support Group May 11, 2006 By Dan Roberts, Founding Director Macular Degeneration Support The retina is the thin lining in the back of the eye, and the macula is at the very center. When the macula is healthy, we are able to see in fine detail. When it […]
Speech for PBA Awards BanquetNovember 2, 2012 Dan RobertsFounding DirectorMacular Degeneration Support Thank you for the privilege of speaking to you this evening, and the opportunity to get to know more of the great people of Prevent Blindness America. I’ve long admired the work of this organization and have referred many of our low vision […]
by Dan Roberts What’s so funny about low vision? Nothing really, but some humor can come from living with it. You know, those gaffes and missteps which may not be funny to anyone who hasn’t lived with visual impairment, but which can make us grin when we realize we’re not the only ones who commit […]
(Featuring “Sarah’s Day”) by Dan Roberts As an unabashed gadget geek, I have followed the development of low vision technology since my diagnosis in 1994. The first fifteen of those years offered a number of optical and non-optical devices to help our low vision community get by, and we have hungrily consumed each and every […]
Eyes are thought to have first developed in animals, in a very basic form, around 550 million years ago. Since then, they have become the second most complex organ after the brain. We hear all the time about the wonderful ways our brains work for us, but our peepers sometimes don’t get the respect they […]
Macugen. Lucentis. Avastin. Eylea. Beovu. All of those are anti-VEGF drugs prescribed for treatment of wet AMD and other conditions involving growth and leakage of new blood vessels in the retina. Those brand names appear in articles and ads, but rarely in eye specialists’ notes and prescription orders. Such names are designed mainly for public […]